TYSABRI -A LETTER FROM BIOGEN IDEC - "To the MS Community"::

"On June 5, 2006, Biogen Idec and Elan announced that the FDA approved a supplemental Biologics License Application (sBLA) for the reintroduction of TYSABRI (natalizumab) as a monotherapy treatment for relapsing forms of multiple sclerosis (MS) to slow the progression of disability and reduce the frequency of clinical relapses. This is an important step forward for people with MS, and we believe TYSABRI offers new hope for those living with this devastating disease.
TYSABRI has demonstrated very promising benefits in patients with relapsing forms of MS. It is the reason why we have worked so diligently to make this product available again to the MS community. At the same time, it is critical that patients and physicians understand the risks of TYSABRI treatment, including the risk of PML. Ultimately, the decision to start TYSABRI will be based on an individual patient's condition and a discussion between physicians and patients of the benefits and risks. Because of these risks, TYSABRI is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies.....[CLICK ABOVE FOR MORE]"